Compare Cassava Sciences Inc (FLNA) vs Vale SA (VALE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cassava Sciences Inc vs Vale SA — how do they compare? Cassava Sciences Inc trades at $1.06 (market cap $53.14M), while Vale SA trades at $14.23 (market cap $61.19B). The key difference: Vale SA is far larger — about 1151.5× Cassava Sciences Inc's market cap, and Vale SA pays a 8.58% dividend while Cassava Sciences Inc pays none. Which is the better fit depends on your goals.
| FLNA | VALE | |
|---|---|---|
Market Cap | $53.14M | $61.19B |
Sector | Health | Basic Materials |
52-Week High | $4.64 | $17.82 |
52-Week Low | $1.09 | $9.53 |
Enterprise Value | -$33.43M | $78.11B |
Dividend Yield | — | 8.58% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FLNA trades at $1.06, down 2.75% today, with a bearish technical signal from moving averages but neutral oscillators. The stock shows a low P/B of 0.78, yet profitability metrics are negative, including a -79.59% ROE and -$90.97M net income for 2025. Recent Q1 2026 earnings beat expectations, and analyst consensus is 66.7% buy. News highlights Q1 financial results and a scientific presentation on TSC-related epilepsy therapies.
Outlook remains speculative due to persistent losses and negative cash flows, offset by strong analyst support and recent earnings beats. Key risks include funding needs for drug development and competitive pressures, while potential upside hinges on clinical progress in TSC-related epilepsy treatments.
VALE trades at $14.27, down 2.19% with a bearish technical signal. The company reported mixed Q1 2026 earnings, missing expectations with EPS of $0.44 versus $0.47 expected. Recent news highlights a $2.56 billion decarbonization investment and governance challenges with board disputes. Cash flow remains positive at $2.42B net for 2025, though revenue has declined from $43.8B in 2022 to $38.4B in 2025.
Analyst consensus is mixed with 40.5% buy ratings and a $17.50 price target suggesting 23% upside. Risks include volatile iron ore prices, rising debt-to-asset ratio to 24.66%, and execution of decarbonization investments. The stock offers value with P/E of 22.23 and EV/EBITDA of 7.33, but faces headwinds from margin compression and geopolitical tensions affecting operations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Cassava Sciences Inc
Cassava Sciences Inc is a clinical-stage biotechnology company engaged in developing a scientific approach for the treatment and detection of Alzheimer's disease. Its therapeutic product candidate is called simufilam, and it is a novel treatment for Alzheimer's disease
Read more on FLNA →About Vale SA
Vale is the world's largest iron ore miner and one of the largest diversified miners, along with BHP and Rio Tinto. Earnings are dominated by the bulk materials division, primarily iron ore and iron ore pellets, with minor contributions from iron ore proxies, including manganese and coal. The base metals division is much smaller, primarily consisting of nickel mines and smelters with a small contribution from copper.
Read more on VALE →
